Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 2 Completed 64 enrolled National Cancer Institute (NCI) NRG Oncology · collab Radiation Therapy Oncology Group · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2007-01-24
Primary completion: 2011-03-09
Completion: 2018-09-04

Outcome

Missed primary endpoint

paper there were no radiographic responses, median overall survival was 7.9 months, median PFS was 1.7 months, and the 6mPFS rate was 6%. PMID 25758746 ↗

paper dasatinib was ineffective in recurrent GBM. PMID 25758746 ↗

Publications

Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral